妊娠期铁缺乏与缺铁性贫血的筛查与补充:美国预防服务工作组更新证据报告与系统综述
本系统综述更新2015年证据,纳入17项补充铁剂的随机临床试验(N=24 023),发现补充铁剂可降低足月时母体缺铁性贫血和铁缺乏风险,但对母婴健康结局无显著改善,且无研究评估妊娠期筛查铁缺乏或缺铁性贫血的获益与危害。
要点
- 补充铁剂可降低足月时母体缺铁性贫血风险(RR 0.40)和铁缺乏风险(RR 0.47)。
- 补充铁剂对妊娠期糖尿病、早产、低出生体重等健康结局无显著差异。
- 无研究评估妊娠期筛查铁缺乏或缺铁性贫血的获益与危害。
核心结论
- 常规产前补充铁剂可降低妊娠期铁缺乏和缺铁性贫血的发生率,但健康结局证据有限或提示无获益。
- 无研究探讨妊娠期筛查铁缺乏或缺铁性贫血,需研究母体铁状态指标变化与健康结局的关联。
研究设计与样本
- 系统综述纳入补充铁剂的随机临床试验及筛查的观察性研究,共17项试验(N=24 023)涉及母体补充铁剂。
- 检索Ovid MEDLINE和Cochrane数据库至2023年5月24日,监测至2024年5月24日,采用随机效应模型合并数据。
主要发现
- 与安慰剂或不补充铁剂相比,补充铁剂与足月时母体缺铁性贫血风险降低相关(4项试验,n=2230;8.6% vs 19.8%;RR 0.40,95%CI 0.26-0.61;I²=20.5%)。
- 与安慰剂或不补充铁剂相比,补充铁剂与足月时母体铁缺乏风险降低相关(6项试验,n=2361;46% vs 70%;RR 0.47,95%CI 0.33-0.67;I²=81.9%)。
- 补充铁剂与安慰剂或不补充相比,母体生活质量、妊娠期糖尿病、母体出血、妊娠期高血压疾病、剖宫产、早产、婴儿低出生体重或小于胎龄儿的发生率无统计学显著差异。
- 补充铁剂的危害包括一过性胃肠道不良反应。
- 无研究评估妊娠期筛查铁缺乏或缺铁性贫血的获益或危害;关于铁状态与健康结局(如妊娠期高血压疾病和早产)关联的数据非常有限。
关键数值与推荐
- 足月时母体缺铁性贫血:补充铁剂组8.6% vs 对照组19.8%,RR 0.40(95%CI 0.26-0.61)。
- 足月时母体铁缺乏:补充铁剂组46% vs 对照组70%,RR 0.47(95%CI 0.33-0.67)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 无研究评估妊娠期筛查铁缺乏或缺铁性贫血的获益或危害。
- 关于铁状态与健康结局(如妊娠期高血压疾病和早产)关联的数据非常有限。
- 健康结局证据有限或提示无获益。
- 足月时母体铁缺乏合并分析异质性I²=81.9%。
- 需研究以理解母体铁状态指标变化与健康结局的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In 2015 the US Preventive Services Task Force (USPSTF) found insufficient evidence to assess the balance of benefits and harms of routine screening and supplementation for iron deficiency anemia during pregnancy. OBJECTIVE: To update the 2015 review on screening for iron deficiency anemia, in addition to iron deficiency during pregnancy, to inform the USPSTF. DATA SOURCES: Ovid MEDLINE and Cochrane databases through May 24, 2023; surveillance through May 24, 2024. STUDY SELECTION: Randomized clinical trials of iron supplementation, screening effectiveness, treatment, and harms; observational studies of screening. DATA EXTRACTION AND SYNTHESIS: Dual review of abstracts, full-text articles, study quality, and data abstraction. Data were pooled using a random-effects model. MAIN OUTCOMES AND MEASURES: Maternal and infant clinical outcomes, hematologic indices, and harms. RESULTS: Seventeen trials (N = 24 023) on maternal iron supplementation were included. Iron supplementation was associated with decreased risk of maternal iron deficiency anemia at term (4 trials, n = 2230; 8.6% vs 19.8%; relative risk, 0.40 [95% CI, 0.26-0.61]; I2 = 20.5%) and maternal iron deficiency at term (6 trials, n = 2361; 46% vs 70%; relative risk, 0.47 [95% CI, 0.33-0.67]; I2 = 81.9%) compared with placebo or no iron supplement. There were no statistically significant differences in maternal quality of life, rates of gestational diabetes, maternal hemorrhage, hypertensive disorders of pregnancy, cesarean delivery, preterm birth, infant low birth weight, or infants small for gestational age for maternal iron supplementation compared with placebo or no supplementation. Harms of iron supplementation included transient gastrointestinal adverse effects. No studies evaluated the benefits or harms of screening for iron deficiency or iron deficiency anemia during pregnancy. Data on the association between iron status and health outcomes, such as hypertensive disorders of pregnancy and preterm birth, were very limited. CONCLUSIONS AND RELEVANCE: Routine prenatal iron supplementation reduces the incidence of iron deficiency and iron deficiency anemia during pregnancy, but evidence on health outcomes is limited or indicates no benefit. No studies addressed screening for iron deficiency or iron deficiency anemia during pregnancy. Research is needed to understand the association between changes in maternal iron status measures and health outcomes.
引用
- Cantor AG, Holmes R, Bougatsos C, et al. Screening and Supplementation for Iron Deficiency and Iron Deficiency Anemia During Pregnancy: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2024. PMID: 39163033. doi:10.1001/jama.2024.13546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。